一项评估艰难梭菌疫苗在65至85岁健康成人中批次一致性、免疫原性、安全性和耐受性的3期研究
这项3期安慰剂对照研究将1317名65至85岁健康成人按1:1:1:1随机分配至3个艰难梭菌疫苗批次或安慰剂组,于第0、1、6月接种200 μg类毒素疫苗或安慰剂。第3剂后1个月,毒素A和B中和抗体几何平均浓度比值的双侧95%CI均在0.5至2之间,达到批次一致性;疫苗耐受性良好,不良事件和严重不良事件率与安慰剂相似。
要点
- 第3剂后1个月,毒素A和B的GMC比值双侧95%CI均在0.5至2之间,批次一致性达成。
- 疫苗组不良事件率36.5%、严重不良事件率4.5%,安慰剂组分别为35.3%和6%。
- 3剂(第0、1、6月)类毒素疫苗在65至85岁健康成人中诱导稳健中和抗体应答且耐受性良好。
核心结论
- 3剂(第0、1、6月)类毒素艰难梭菌疫苗在65至85岁健康参与者中诱导稳健的中和抗体应答且耐受性良好。
- 批次间一致性极佳,表明该艰难梭菌疫苗制剂的生产工艺控制良好。
研究设计与样本
- 3期、安慰剂对照研究,将1317名65至85岁健康成人按1:1:1:1随机分配至3个艰难梭菌疫苗批次或安慰剂组。
- 参与者于第0、1、6月接种艰难梭菌疫苗(总类毒素200 μg)或安慰剂。
- 主要免疫原性目标为第3剂后1个月毒素A和B特异性中和抗体几何平均浓度(GMC)比值的双侧95%CI在0.5至2之间,以评估批次间一致性。
- 安全性结局包括接种后7天内的局部反应和全身事件、不良事件(AEs)和严重不良事件(SAEs)。
主要发现
- 1317名入组参与者中1218名完成研究。
- 第3剂后1个月毒素A中和抗体GMC(95%CI):批次1为878.8(786.3, 982.2),批次2为873.0(779.2, 978.1),批次3为872.9(782.6, 973.5)。
- 第3剂后1个月毒素B中和抗体GMC(95%CI):批次1为5823.9(5041.0, 6728.4),批次2为5462.8(4733.4, 6304.7),批次3为5426.0(4724.4, 6231.8)。
- 毒素A和B的GMC比值双侧95%CI均在0.5至2之间,表明批次间一致性达成。
- 疫苗耐受性良好,各疫苗批次间局部反应和全身事件发生率相似;疫苗组AE率36.5%、SAE率4.5%,安慰剂组AE率35.3%、SAE率6%。
关键数值与推荐
- 批次间一致性标准:GMC比值的双侧95%CI在0.5至2之间,毒素A和B均达到。
- 毒素A第3剂后1个月GMC(95%CI):批次1 878.8(786.3, 982.2)、批次2 873.0(779.2, 978.1)、批次3 872.9(782.6, 973.5)。
- 毒素B第3剂后1个月GMC(95%CI):批次1 5823.9(5041.0, 6728.4)、批次2 5462.8(4733.4, 6304.7)、批次3 5426.0(4724.4, 6231.8)。
- AE率:疫苗组36.5% vs 安慰剂组35.3%;SAE率:疫苗组4.5% vs 安慰剂组6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A toxoid-based Clostridioides difficile vaccine is currently in development. Here, we report lot-to-lot consistency, immunogenicity, safety, and tolerability of 3 C difficile vaccine doses in healthy older adults. METHODS: This phase 3, placebo-controlled study randomized (1:1:1:1) healthy adults 65 to 85 years of age to 1 of 3 C difficile vaccine lots or placebo. Participants received C difficile vaccine (200 μg total toxoid) or placebo (Months 0, 1, 6). The primary immunogenicity objective was lot-to-lot consistency (2-sided 95 % CIs within 0.5 and 2 for comparisons of geometric mean concentration [GMC] ratios) for toxins A- and B-specific neutralizing antibody levels 1 month after Dose 3. Safety outcomes included local reactions and systemic events ≤7 days after vaccination, adverse events (AEs), and serious AEs (SAEs). RESULTS: Of 1317 enrolled participants, 1218 completed the study. C difficile vaccine immunogenicity was consistent across lots, with neutralizing antibody responses 1 month after Dose 3 for both toxin A (GMC [95 % CI]: lot 1, 878.8 [786.3, 982.2]; lot 2, 873.0 [779.2, 978.1]; lot 3, 872.9 [782.6, 973.5]) and toxin B (lot 1, 5823.9 [5041.0, 6728.4]; lot 2, 5462.8 [4733.4, 6304.7]; lot 3, 5426.0 [4724.4, 6231.8]). Two-sided 95 % CIs for GMC ratios were within 0.5 and 2 for toxins A and B, indicating lot-to-lot consistency was achieved. C difficile vaccine was well tolerated, with similar rates of local reactions and systemic events among vaccine lots. AE and SAE rates were similar across C difficile vaccine (36.5 % and 4.5 %, respectively) and placebo (35.3 % and 6 %). CONCLUSIONS: Three doses (Months 0,1,6) of toxoid-based C difficile vaccine induced robust neutralizing antibody responses and were well tolerated in healthy participants 65 to 85 years of age. Lot-to-lot consistency was excellent, indicating the manufacturing process for this C difficile vaccine formulation was well controlled. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03579459.
引用
- Christensen S, Bouguermouh S, Ilangovan K, et al. A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age. Vaccine. 2023. PMID: 37977942. doi:10.1016/j.vaccine.2023.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。